Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. develops clinical-stage treatments for rare diseases and diseases with high unmet need, with news centered on anti-infective programs for multi-drug resistant bacterial infections. Updates frequently cover tebipenem HBr, an investigational oral carbapenem antibiotic for complicated urinary tract infections, including pyelonephritis, and its licensed development and commercialization relationship with GSK outside certain Asian territories.
Company announcements also report quarterly and annual operating results, business updates, clinical data presentations, FDA submission activity, portfolio-expansion efforts, cash runway commentary, and equity-compensation grants under Nasdaq rules.
Spero Therapeutics (Nasdaq: SPRO) provided updates on its clinical programs and financial performance for Q4 and full-year 2021. The FDA identified deficiencies in the NDA review for tebipenem HBr, impacting labeling discussions, but a meeting is scheduled to address these issues. Spero expects a commercial launch of tebipenem HBr in 2H 2022, pending approval. The company reported a net loss of $89.8 million for 2021, with total revenue rising to $18.3 million. Ongoing trials for SPR720 and SPR206 show potential for future development and value creation.
Spero Therapeutics (Nasdaq: SPRO) will hold a conference call on March 31, 2022, at 4:30 p.m. ET to discuss its fourth quarter and full-year 2021 financial results and provide a business update. The call can be accessed via phone or a live audio webcast available on Spero's website. Spero focuses on creating novel treatments for multi-drug-resistant bacterial infections, with its lead candidate, tebipenem HBr, recently receiving FDA NDA acceptance. This investigational drug aims to address complicated urinary tract infections but is not yet approved.
Spero Therapeutics announced positive results from its Phase 1 bronchoalveolar lavage (BAL) clinical trial for SPR206, its next-generation polymyxin candidate, which targets drug-resistant gram-negative infections. With a well-tolerated profile, the drug showed a lung epithelial lining fluid to plasma concentration ratio of 0.264, ensuring effective dosing against targeted pathogens. The findings support advancement into further clinical trials for hospital-acquired and ventilator-associated pneumonia. SPR206 has the potential to address critical treatment gaps for patients with serious bacterial lung infections.
Spero Therapeutics has expanded its partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop tebipenem for treating complicated urinary tract infections (cUTI) in pediatric patients. The contract extension increases potential funding to $59.7 million, with an additional $12.9 million allocated for a clinical trial. Spero's New Drug Application for tebipenem HBr is currently under review by the FDA. This collaboration addresses treatment options for multi-drug resistant infections, enhancing Spero's clinical pipeline.
Spero Therapeutics (Nasdaq: SPRO) announced the FDA lifted the clinical hold on its Phase 2 trial for SPR720, aimed at treating nontuberculous mycobacterial (NTM) disease. This decision allows Spero to resume clinical development, with plans to initiate the trial in the second half of 2022. SPR720 is designed as a once-daily oral treatment, addressing a significant unmet need for patients suffering from NTM-PD. The program has received FDA's Qualified Infectious Disease Product and orphan drug designations, indicating its potential significance in the market.
Spero Therapeutics (Nasdaq: SPRO) announced that the FDA has granted Priority Review for its New Drug Application (NDA) for tebipenem HBr, an oral antibiotic aimed at treating complicated urinary tract infections (cUTI). The target action date for the NDA is June 27, 2022. Tebipenem HBr has received multiple designations, including Qualified Infectious Disease Product and Fast Track. Positive data from the Phase 3 ADAPT-PO trial support this application, indicating non-inferiority to existing IV treatments. The company anticipates launching the product in the second half of 2022.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced that CEO Ankit Mahadevia will present at two upcoming virtual healthcare conferences: the Piper Sandler 33rd Annual Conference from November 29 to December 2, 2021, and the Evercore ISI HealthCONx Conference from November 30 to December 2, 2021. The Piper Sandler presentation will be available on-demand starting November 24 at 2:00 PM ET, while the Evercore presentation is scheduled for December 1 at 3:05 PM ET. Webcasts can be accessed via Spero's website, where replays will also be available.
Spero Therapeutics, Inc. (Nasdaq: SPRO) submitted an NDA to the U.S. FDA for its oral antibiotic, tebipenem HBr, targeting complicated urinary tract infections (cUTI), with a potential launch in H2 2022. Additionally, the company entered a non-dilutive revenue financing agreement with HealthCare Royalty Partners for up to $125 million, enhancing its financial position. The third-quarter report shows a net loss of $22.5 million, down from $18.9 million the prior year, with total revenues at $3.1 million. Despite these challenges, Spero's cash reserves of $123.4 million should sustain operations into Q4 2022.
Spero Therapeutics, Inc. (Nasdaq: SPRO) will host a conference call on November 10, 2021, at 4:30 p.m. ET to discuss its Q3 2021 financial results and provide updates on its business and pipeline. The company focuses on developing treatments for multi-drug resistant bacterial infections and rare diseases. Spero's lead candidate, tebipenem HBr, is under review with a new drug application filed after positive Phase 3 trial results. Other developments include an oral therapy for NTM infections and an IV-administered polymyxin product for treating MDR infections.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the submission of a New Drug Application (NDA) to the FDA for tebipenem HBr tablets, aimed at treating complicated urinary tract infections (cUTI). This marks a significant advancement as tebipenem HBr would be the first oral carbapenem antibiotic for cUTI if approved. Data from the Phase 3 ADAPT-PO trial confirmed its effectiveness, showing non-inferiority to IV ertapenem. The anticipated launch is set for the second half of 2022, which could reduce healthcare resource utilization by shifting from IV to oral treatments.